Home
/
Revolution Medicines, Inc.
/
Financials
/
Quarterly
Revolution Medicines, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Revolution Medicines, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2024
Sep 30, 2024
$0
Nov 6, 2024
Q2
2024
Jun 30, 2024
$0
Aug 7, 2024
Q1
2024
Mar 31, 2024
$0
May 8, 2024
Q3
2024
Sep 30, 2023
$0
Nov 6, 2024
Q1
2023
Jun 30, 2023
$3.82M
Aug 8, 2023
Q2
2024
Jun 30, 2023
$3.82M
Aug 7, 2024
Q1
2024
Mar 31, 2023
$7.01M
May 8, 2024
Q3
2023
Sep 30, 2022
$3.36M
Nov 6, 2023
Q1
2023
Jun 30, 2022
$9.12M
Aug 8, 2023
Q2
2022
Jun 30, 2022
$9.12M
Aug 9, 2022
Q1
2023
Mar 31, 2022
$7.58M
May 8, 2023
Q3
2022
Sep 30, 2021
$1.10M
Nov 7, 2022
Q2
2022
Jun 30, 2021
$8.70M
Aug 9, 2022
Q1
2022
Mar 31, 2021
$10.13M
May 9, 2022
Q3
2021
Sep 30, 2020
$12.66M
Nov 10, 2021
Q2
2021
Jun 30, 2020
$10.03M
Aug 11, 2021
Q1
2021
Mar 31, 2020
$11.55M
May 10, 2021
Q3
2020
Sep 30, 2019
$12.51M
Nov 12, 2020
Q2
2020
Jun 30, 2019
$12.28M
Aug 10, 2020
Q1
2020
Mar 31, 2019
$13.17M
May 14, 2020
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($305.21M)
Nov 5, 2025
Q3
2025
Jun 30, 2025
($247.79M)
Nov 5, 2025
Q2
2025
Jun 30, 2025
($247.79M)
Aug 6, 2025
Q3
2025
Mar 31, 2025
($213.42M)
Nov 5, 2025
Q1
2025
Mar 31, 2025
($213.42M)
May 7, 2025
Q2
2025
Mar 31, 2025
($213.42M)
Aug 6, 2025
Q3
2025
Sep 30, 2024
($156.29M)
Nov 5, 2025
Q2
2025
Jun 30, 2024
($133.23M)
Aug 6, 2025
Q3
2025
Jun 30, 2024
($133.23M)
Nov 5, 2025
Q2
2025
Mar 31, 2024
($116.00M)
Aug 6, 2025
Q1
2025
Mar 31, 2024
($116.00M)
May 7, 2025
Q3
2025
Mar 31, 2024
($116.00M)
Nov 5, 2025
Q3
2024
Sep 30, 2023
($108.43M)
Nov 6, 2024
Q3
2024
Jun 30, 2023
($98.30M)
Nov 6, 2024
Q1
2023
Jun 30, 2023
($98.30M)
Aug 8, 2023
Q2
2024
Jun 30, 2023
($98.30M)
Aug 7, 2024
Q1
2024
Mar 31, 2023
($68.10M)
May 8, 2024
Q2
2024
Mar 31, 2023
($68.10M)
Aug 7, 2024
Q3
2024
Mar 31, 2023
($68.10M)
Nov 6, 2024
Q3
2023
Sep 30, 2022
($73.33M)
Nov 6, 2023
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($315.27M)
Nov 5, 2025
Q2
2025
Jun 30, 2025
($264.71M)
Aug 6, 2025
Q1
2025
Mar 31, 2025
($240.76M)
May 7, 2025
Q3
2025
Sep 30, 2024
($175.71M)
Nov 5, 2025
Q2
2025
Jun 30, 2024
($156.64M)
Aug 6, 2025
Q1
2025
Mar 31, 2024
($140.86M)
May 7, 2025
Q3
2024
Sep 30, 2023
($123.25M)
Nov 6, 2024
Q1
2023
Jun 30, 2023
($108.80M)
Aug 8, 2023
Q2
2024
Jun 30, 2023
($108.80M)
Aug 7, 2024
Q1
2024
Mar 31, 2023
($75.16M)
May 8, 2024
Q3
2023
Sep 30, 2022
($76.53M)
Nov 6, 2023
Q2
2022
Jun 30, 2022
($62.09M)
Aug 9, 2022
Q1
2023
Jun 30, 2022
($62.09M)
Aug 8, 2023
Q1
2023
Mar 31, 2022
($57.95M)
May 8, 2023
Q3
2022
Sep 30, 2021
($53.16M)
Nov 7, 2022
Q2
2022
Jun 30, 2021
($44.54M)
Aug 9, 2022
Q1
2022
Mar 31, 2021
($37.40M)
May 9, 2022
Q3
2021
Sep 30, 2020
($27.55M)
Nov 10, 2021
Q2
2021
Jun 30, 2020
($27.98M)
Aug 11, 2021
Q1
2021
Mar 31, 2020
($21.08M)
May 10, 2021